稳外资外贸，泰州创新服务护航药企“出海”

Core Insights - Anruweita Pharmaceutical successfully completed a €30 million order for capsule products to the EU, aided by innovative service models from the Taizhou biopharmaceutical industry service team [1][2] - The company, a wholly-owned subsidiary of Indian Aravind Pharmaceuticals, benefited from a "zero-distance" government-enterprise collaboration that exemplifies high-quality development in the biopharmaceutical sector [1][2] Group 1 - In early 2023, Anruweita Pharmaceutical received a contract manufacturing order from EU clients for capsule drugs, which required compliance with GMP certification [2] - The Taizhou biopharmaceutical industry service team quickly responded to regulatory challenges by proposing a "breakthrough and classified strategy," leading to expedited GMP inspections and approvals [2][3] - The service team coordinated with provincial drug regulatory authorities to optimize export filing processes, significantly reducing approval timelines [3] Group 2 - The establishment of the Taizhou biopharmaceutical industry collaborative "going abroad" development alliance in 2025 aims to support market expansion and cross-border logistics for enterprises [3] - The alliance will provide training and resources to help companies leverage production capacity, drug research and development, and industry chain collaboration for international market entry [3] - Continuous improvement of face-to-face service mechanisms has been emphasized, with recent efforts addressing 30 enterprise requests related to innovative drug approvals and cross-border data compliance [3][4] Group 3 - The Taizhou market regulatory department is committed to enhancing innovation and quality in the pharmaceutical industry through various service mechanisms and platforms [4] - The department aims to act as a "gold medal service provider" to strengthen the competitiveness of the pharmaceutical industry ecosystem [4]